论文部分内容阅读
目的观察雷珠单抗注射液(RZB)玻璃体腔内注射联合黄斑格栅样光凝(MGP)治疗糖尿病黄斑水肿(DME)患者的临床效果。方法 85例DME患者,随机分为对照组(42例)和观察组(43例),对照组患者予以MGP治疗,观察组患者在此基础上联合RZB玻璃体腔内注射,比较两组疗效及并发症。结果两组患者治疗后的黄斑区域平均厚度(CAT)、黄斑中心凹厚度(CST)、最佳矫正视力(BCVA)水平均较治疗前下降,且观察组下降幅度大于对照组(P<0.05)。对照组患者的眼压升高、结膜出血、前房反应的例数分别为2、3、4例,总并发症发生率为21.43%;观察组患者的眼压升高、结膜出血、前房反应的例数分别为0、1、1例,总并发症发生率为4.65%,对照组的总并发症发生率高于观察组(P<0.05)。结论以玻璃体腔内注射RZB联合MGP治疗能有效改善DME患者黄斑情况,提高视力,且并发症少,具有临床推广价值。
Objective To observe the clinical effect of intravitreal injection of granulocyte-macular grid photocoagulation (MGP) with ranibizumab injections (RZB) in patients with diabetic macular edema (DME). Methods Eighty-five DME patients were randomly divided into control group (n = 42) and observation group (n = 43). Patients in the control group were treated with MGP. The patients in the observation group were treated with intravitreal injection of RZB. The curative effect and complications disease. Results The mean macular thickness (CAT), macular foveal thickness (CST) and best corrected visual acuity (BCVA) in both groups after treatment were significantly lower than those before treatment, and the decrease in the observation group was greater than that in the control group (P <0.05) . In the control group, the intraocular pressure (IOP), conjunctival hemorrhage and the number of anterior chamber reactions were 2, 3 and 4 cases, respectively, and the total complication rate was 21.43%. In the observation group, the intraocular pressure, conjunctival hemorrhage, The number of response cases were 0, 1 and 1, respectively. The overall complication rate was 4.65%. The overall complication rate of the control group was higher than that of the observation group (P <0.05). Conclusion Intravitreal injection of RZB combined with MGP can effectively improve the macular conditions in DME patients and improve visual acuity with less complications and clinical value.